施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

休市中 06-12 16:00:00 EDT

57.13

+0.23

+0.40%

盘后57.20

+0.07+0.12%

19:59 EDT

最高57.60	最低56.77	成交量784.06万
今开57.45	昨收56.90	日振幅1.46%
总市值1,163亿	流通市值1,161亿	总股本20.36亿
成交额4.48亿	换手率0.39%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":57.13,"timestamp":1781294400000,"preClose":56.9,"halted":0,"volume":7840587,"hourTrading":{"tag":"盘后","latestPrice":57.1985,"preClose":57.13,"latestTime":"19:59 EDT","volume":331674,"amount":18948425.3449,"timestamp":1781308782545,"change":0.0685,"changeRate":0.001199,"amplitude":0.003501},"delay":0,"changeRate":0.004042179261862988,"floatShares":2031646263,"shares":2035753027,"eps":3.569767,"marketStatus":"休市中","change":0.23,"latestTime":"06-12 16:00:00 EDT","open":57.45,"high":57.6,"low":56.77,"amount":447708870.869976,"amplitude":0.014587,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.569767,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":56.9,"dividendRate":0.043723,"preHourTrading":{"tag":"盘前","latestPrice":57.37,"preClose":56.91,"latestTime":"09:29 EDT","volume":1760,"amount":100229.21568,"timestamp":1781270999321,"change":0.46,"changeRate":0.008083,"amplitude":0.011422},"postHourTrading":{"tag":"盘后","latestPrice":57.1985,"preClose":57.13,"latestTime":"19:59 EDT","volume":331674,"amount":18948425.3449,"timestamp":1781308782545,"change":0.0685,"changeRate":0.001199,"amplitude":0.003501},"volumeRatio":0.7698854132510361,"impliedVol":0.27,"impliedVolPercentile":0.1594},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"1145683800","title":"异动解读｜施贵宝盘中上涨3.13%，多重利好叠加行业回暖共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1145683800","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145683800?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:35","pubTimestamp":1780583737,"startTime":"0","endTime":"0","summary":"6月4日，施贵宝盘中上涨3.13%，报56.09美元/股，成交额1.59亿美元。此外，杰富瑞将公司目标价从70美元上调至73美元，维持买入评级。当日制药行业整体表现强势，礼来涨4.54%，诺和诺德涨4.43%，默沙东涨3.62%，板块联动亦对股价形成支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134800758","title":"百时美施贵宝：Iza-Bren在重度经治患者群体中展现可控安全性，未观察到新的安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1134800758","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134800758?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:04","pubTimestamp":1780401860,"startTime":"0","endTime":"0","summary":"百时美施贵宝（Bristol-Myers Squibb）公布的数据显示，其药物组合Iza-Bren在重度经治的患者群体中表现出可控的安全性特征。研究期间，未观察到任何新的安全信号。这一结果对于此前已接受过多种治疗方案的患者而言，具有积极的临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1989771016.USD","LU1868836591.USD","LU2125154778.USD","IE0002141913.USD","BK4532","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU0096364046.USD","LU1261432733.SGD","LU1571399168.USD","LU1585245621.USD","LU1718418525.SGD","LU1670711123.USD","LU1670710588.SGD","LU0321505868.SGD","LU1093756168.USD","LU1868836757.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU0456855351.SGD","LU1074936037.SGD","LU1670710661.SGD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU0306807586.USD","IE00BFXG1179.USD","LU1868836914.USD","LU1868837136.USD","LU2133065610.SGD","BK4534","LU1868837300.USD","LU2242646821.SGD","LU0985481810.HKD","LU1323610961.USD","LU0114720955.EUR","LU1670711040.USD","LU0321505439.SGD","LU1291159041.SGD","LU2242652126.USD","LU0061475181.USD","LU0432979614.USD","LU1983299246.USD","LU0267386448.USD","LU1430594728.SGD","LU0237698245.USD","LU1883839398.USD","BMY","LU0306806265.USD","LU2360032135.SGD","BK4559","LU1032466523.USD","LU2125154935.USD","BK4585","BK4581","BK4588","LU0882574055.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130883268","title":"施贵宝Izalontamab Brengitecan在TNBC和ESCC中展现显著的OS与PFS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1130883268","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130883268?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:01","pubTimestamp":1780401706,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其候选药物Izalontamab Brengitecan在三阴性乳腺癌和食管鳞状细胞癌的临床试验中，取得了总生存期与无进展生存期的显著改善。这一积极数据为相关癌症患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0237698245.USD","BK4559","IE0009355771.USD","LU0321505868.SGD","LU0225771236.USD","LU1670711040.USD","LU1983299246.USD","BMY","LU1291159041.SGD","LU1032466523.USD","LU1093756168.USD","LU1670710661.SGD","LU1571399168.USD","LU1261432733.SGD","LU0456855351.SGD","LU1868836914.USD","LU1585245621.USD","IE00BSNM7G36.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0868494617.USD","LU0985481810.HKD","LU0096364046.USD","BK4007","BK4585","LU1989771016.USD","LU1868837136.USD","LU2125154935.USD","BK4532","LU1670711123.USD","IE0002141913.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0306806265.USD","LU0882574055.USD","LU2242652126.USD","LU1883839398.USD","LU2242646821.SGD","BK4534","LU1074936037.SGD","LU0432979614.USD","LU1868836591.USD","LU1093756325.SGD","LU2125154778.USD","LU2133065610.SGD","LU2360032135.SGD","LU0114720955.EUR","LU0306807586.USD","LU1718418525.SGD","IE00BFXG1179.USD","LU0321505439.SGD","BK4588","LU1323610961.USD","LU1430594728.SGD","LU1670710588.SGD","BK4581","LU1868836757.USD","LU0267386448.USD","IE00BJJMRZ35.SGD","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132733869","title":"异动解读｜施贵宝盘中下跌3.1%，报55.2美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132733869","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132733869?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:23","pubTimestamp":1780323800,"startTime":"0","endTime":"0","summary":"6月1日，施贵宝盘中下跌3.1%，报55.2美元/股，成交额1.68亿美元。施贵宝所在的制药行业中，整体表现疲软，个股中，礼来跌2.2%，强生跌1.51%，辉瑞跌2.08%，默沙东跌2.84%，诺和诺德跌2.39%。百时美施贵宝公司是一家生物制药公司，专注于创新药物的发现、开发、许可、生产、营销和销售，优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124846858","title":"FDA优先审评施贵宝Camzyos补充新药申请，用于治疗青少年症状性梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1124846858","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124846858?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:00","pubTimestamp":1780311638,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已接受施贵宝（Bristol-Myers Squibb）提交的Camzyos（Mavacamten）补充新药申请，并授予其优先审评资格。该申请旨在扩展该药物的适应症，用于治疗青少年患者的症状性梗阻性肥厚型心肌病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0306806265.USD","BK4588","LU1868836914.USD","BK4532","IE0009355771.USD","LU1261432733.SGD","LU1868836591.USD","LU1571399168.USD","LU1074936037.SGD","LU0225284248.USD","IE00BFXG1179.USD","LU1032466523.USD","IE0002141913.USD","LU1670710661.SGD","LU0061475181.USD","LU0114720955.EUR","LU0225771236.USD","LU2133065610.SGD","IE00BJT1NW94.SGD","LU0321505439.SGD","LU0267386448.USD","IE00BFTCPJ56.SGD","LU2360032135.SGD","LU1323610961.USD","LU1093756168.USD","LU0237698245.USD","LU0985481810.HKD","LU1670711123.USD","LU0868494617.USD","LU1670711040.USD","LU1093756325.SGD","LU1989771016.USD","LU2125154935.USD","BK4585","IE00BSNM7G36.USD","LU2125154778.USD","LU1883839398.USD","BK4534","BK4007","LU1868836757.USD","LU1291159041.SGD","LU0096364046.USD","LU1983299246.USD","LU1868837136.USD","BK4559","IE00B2B36J28.USD","LU0321505868.SGD","BMY","LU1868837300.USD","LU1670710588.SGD","LU0882574055.USD","LU1430594728.SGD","LU0306807586.USD","LU1718418525.SGD","LU0432979614.USD","LU2242652126.USD","LU1585245621.USD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120138167","title":"施贵宝免疫疗法组合获批用于治疗既往未治疗的III/IV期经典霍奇金淋巴瘤成人与青少年患者（12岁及以上）","url":"https://stock-news.laohu8.com/highlight/detail?id=1120138167","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120138167?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:59","pubTimestamp":1780311545,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其免疫疗法组合方案已获得监管批准，适用于治疗既往未接受过治疗的III期或IV期经典霍奇金淋巴瘤（CHL）患者，覆盖年龄在12岁及以上的成人和青少年人群。这一批准标志着该疗法应用范围的进一步扩大，为更广泛的患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU1291159041.SGD","LU1323610961.USD","LU1571399168.USD","LU1883839398.USD","LU1093756325.SGD","LU1670711040.USD","LU0306807586.USD","LU0456855351.SGD","LU1670710661.SGD","LU0225771236.USD","LU1032466523.USD","LU1868837136.USD","LU0096364046.USD","LU2125154778.USD","BK4559","BK4534","BK4588","LU1670711123.USD","LU2125154935.USD","LU2360032135.SGD","IE00BJJMRZ35.SGD","LU0432979614.USD","BK4585","IE00BFXG1179.USD","LU0267386448.USD","LU0306806265.USD","LU1585245621.USD","LU1868836591.USD","LU0061475181.USD","LU1074936037.SGD","LU1989771016.USD","IE00BFTCPJ56.SGD","LU1868837300.USD","BK4581","LU1868836757.USD","BK4007","LU2133065610.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","LU0985481810.HKD","LU1670710588.SGD","LU0868494617.USD","LU0882574055.USD","BK4532","BMY","IE0009355771.USD","LU0321505868.SGD","LU1261432733.SGD","LU0237698245.USD","LU2242652126.USD","LU0321505439.SGD","LU1868836914.USD","IE0002141913.USD","LU1093756168.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU1430594728.SGD","LU0225284248.USD","IE00B2B36J28.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168315798","title":"施贵宝宣布欧狄沃®联合AVD疗法获欧盟扩大标签，获批用于一线治疗晚期经典型霍奇金淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1168315798","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168315798?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:55","pubTimestamp":1780311348,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其欧狄沃®（纳武利尤单抗）联合AVD化疗方案，已获得欧盟监管机构批准扩大标签，可用于一线治疗晚期经典型霍奇金淋巴瘤。这一决定标志着该免疫联合疗法在欧洲的应用范围得到进一步拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU0868494617.USD","LU0985481810.HKD","LU2133065610.SGD","LU1868836757.USD","LU1868837300.USD","LU1989771016.USD","LU1571399168.USD","BK4534","LU1074936037.SGD","LU0321505439.SGD","BK4559","LU2242646821.SGD","LU1670711040.USD","LU0882574055.USD","IE00BFTCPJ56.SGD","LU0321505868.SGD","LU1261432733.SGD","LU1670711123.USD","BK4581","LU0306806265.USD","LU1718418525.SGD","IE0009355771.USD","LU1983299246.USD","LU0267386448.USD","LU1093756325.SGD","LU0237698245.USD","BMY","LU1868837136.USD","LU0225771236.USD","LU1670710588.SGD","LU1868836914.USD","LU0061475181.USD","LU2125154935.USD","IE0002141913.USD","BK4588","LU2242652126.USD","LU2360032135.SGD","LU1868836591.USD","LU0432979614.USD","LU1291159041.SGD","LU0306807586.USD","IE00BJT1NW94.SGD","LU1670710661.SGD","BK4532","LU2125154778.USD","LU0456855351.SGD","BK4007","LU0225284248.USD","IE00BJJMRZ35.SGD","IE00BFXG1179.USD","BK4585","IE00B2B36J28.USD","LU1032466523.USD","LU1430594728.SGD","LU0114720955.EUR","LU0096364046.USD","IE00BSNM7G36.USD","LU1093756168.USD","LU1883839398.USD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143833745","title":"施贵宝：Mezikd显著提升二/三线及高危疾病患者无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1143833745","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143833745?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:00","pubTimestamp":1780056024,"startTime":"0","endTime":"0","summary":"施贵宝公司公布的数据显示，其药物Mezikd在改善患者无进展生存期方面取得了显著成效。这一积极结果覆盖了两个关键的患者群体：接受过二线或三线治疗的患者，以及那些患有更高风险疾病的患者。\n研究结果表明，Mezikd疗法为这些通常预后更具挑战性的患者带来了新的希望。无进展生存期是衡量癌症治疗效果的关键指标，其显著改善意味着疾病进展被有效延缓。这对于临床治疗决策和患者长期管理具有重要指导意义。\n该数据的公布进一步巩固了Mezikd在相关治疗领域的潜力，也为施贵宝公司的产品管线增添了有力证据。后续进展值得市场与医学界持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1983299246.USD","LU0868494617.USD","LU0306806265.USD","LU0321505868.SGD","LU0306807586.USD","LU1291159041.SGD","LU1670710661.SGD","LU0237698245.USD","LU2242646821.SGD","LU1032466523.USD","LU0225771236.USD","IE00BFXG1179.USD","IE00B2B36J28.USD","IE0002141913.USD","LU1868836757.USD","BK4559","LU2242652126.USD","LU0432979614.USD","LU1261432733.SGD","LU0985481810.HKD","IE0009355771.USD","LU1074936037.SGD","BK4007","LU1093756325.SGD","LU1718418525.SGD","LU2360032135.SGD","LU1883839398.USD","LU1868837300.USD","LU1989771016.USD","BMY","LU0114720955.EUR","LU1868837136.USD","LU2125154935.USD","LU2133065610.SGD","LU1571399168.USD","IE00BJT1NW94.SGD","LU2125154778.USD","LU1868836591.USD","LU1585245621.USD","BK4581","IE00BSNM7G36.USD","LU0321505439.SGD","LU0061475181.USD","LU0267386448.USD","LU0096364046.USD","LU1670711123.USD","LU0225284248.USD","LU1093756168.USD","BK4534","LU1868836914.USD","LU1670710588.SGD","BK4532","BK4585","IE00BJJMRZ35.SGD","LU0882574055.USD","LU1670711040.USD","LU1323610961.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160502097","title":"施贵宝：Mezikd安全性特征与已知的Mezigdomide及联合疗法特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1160502097","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160502097?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:00","pubTimestamp":1780056024,"startTime":"0","endTime":"0","summary":"施贵宝公司公布的数据显示，其研究中的药物Mezikd的安全性特征，与已知的Mezigdomide及联合治疗方案的特征保持一致。这一发现为相关疗法的进一步开发提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","BK4588","LU1074936037.SGD","IE00BSNM7G36.USD","LU2125154935.USD","LU0225771236.USD","LU1093756325.SGD","LU2360032135.SGD","BK4581","LU2242646821.SGD","BK4534","LU2125154778.USD","LU1868837300.USD","LU1571399168.USD","LU1670711123.USD","IE00BFTCPJ56.SGD","LU0306806265.USD","LU1585245621.USD","IE00BFXG1179.USD","LU1868836914.USD","LU1868837136.USD","LU0432979614.USD","IE00BJT1NW94.SGD","BK4532","LU0061475181.USD","LU0306807586.USD","LU1868836591.USD","LU1868836757.USD","LU1883839398.USD","LU1989771016.USD","LU1670711040.USD","LU0868494617.USD","LU0985481810.HKD","LU0114720955.EUR","LU1032466523.USD","LU1430594728.SGD","IE00B2B36J28.USD","LU0321505439.SGD","LU2133065610.SGD","LU1093756168.USD","LU0882574055.USD","IE0002141913.USD","IE0009355771.USD","LU1670710661.SGD","LU2242652126.USD","BK4559","LU1323610961.USD","BK4007","LU0267386448.USD","LU1291159041.SGD","BK4585","LU0456855351.SGD","LU0096364046.USD","LU1670710588.SGD","LU0321505868.SGD","LU1261432733.SGD","LU0237698245.USD","LU1718418525.SGD","LU1983299246.USD","BMY","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138660916","title":"施贵宝：Mezikd在复发或难治性多发性骨髓瘤中，较标准疗法降低疾病进展/死亡风险超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138660916","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138660916?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:00","pubTimestamp":1780056024,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其药物Mezikd在治疗复发或难治性多发性骨髓瘤的临床试验中，取得了显著成果。数据显示，与现行标准疗法相比，Mezikd能够将患者的疾病进展或死亡风险降低超过50%。这一结果凸显了该药物在改善这类难治性血液癌症患者临床结局方面的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU1670711040.USD","LU1868837136.USD","LU2125154778.USD","LU1989771016.USD","LU0306806265.USD","LU0237698245.USD","LU0321505868.SGD","LU0985481810.HKD","LU1571399168.USD","LU2125154935.USD","LU0868494617.USD","LU0456855351.SGD","LU1585245621.USD","LU1670710588.SGD","LU0096364046.USD","BK4532","LU1430594728.SGD","BK4581","LU1261432733.SGD","LU1868836757.USD","LU1868836914.USD","LU0882574055.USD","BK4559","IE0009355771.USD","LU1983299246.USD","LU1032466523.USD","LU0306807586.USD","LU0267386448.USD","IE00B2B36J28.USD","LU2242652126.USD","BK4534","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU1883839398.USD","BMY","BK4588","LU1093756168.USD","LU1093756325.SGD","LU1868837300.USD","LU1323610961.USD","LU2242646821.SGD","LU2360032135.SGD","LU1718418525.SGD","LU1868836591.USD","LU1670710661.SGD","LU1291159041.SGD","LU1074936037.SGD","LU1670711123.USD","IE00BFXG1179.USD","LU0432979614.USD","LU0061475181.USD","IE00BJT1NW94.SGD","LU0225771236.USD","BK4007","LU0225284248.USD","LU0321505439.SGD","LU2133065610.SGD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132774432","title":"施贵宝：Mezikd展现更高总体缓解率及完全缓解或更佳疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1132774432","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132774432?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:00","pubTimestamp":1780056020,"startTime":"0","endTime":"0","summary":"施贵宝公布的数据显示，其药物Mezikd在临床试验中取得了更高的总体缓解率，并且观察到达到完全缓解或更佳疗效的患者比例有所提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670710661.SGD","LU2125154778.USD","LU2133065610.SGD","LU1868837136.USD","BK4007","IE00B2B36J28.USD","BK4532","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU1093756168.USD","BK4534","IE00BJJMRZ35.SGD","LU2125154935.USD","LU1670711123.USD","LU0267386448.USD","BK4588","LU0432979614.USD","LU0321505439.SGD","LU1093756325.SGD","LU1883839398.USD","LU1868837300.USD","IE00BFXG1179.USD","LU0096364046.USD","LU0225284248.USD","LU0306807586.USD","LU1323610961.USD","LU1571399168.USD","LU0114720955.EUR","LU1261432733.SGD","IE0009355771.USD","LU0237698245.USD","LU1670710588.SGD","LU0306806265.USD","BMY","IE0002141913.USD","LU1989771016.USD","LU2242646821.SGD","LU0321505868.SGD","LU2360032135.SGD","LU1074936037.SGD","LU2242652126.USD","LU1585245621.USD","LU0985481810.HKD","LU0061475181.USD","LU0225771236.USD","LU0868494617.USD","BK4585","LU1868836914.USD","LU1718418525.SGD","BK4581","LU0456855351.SGD","LU1868836757.USD","LU1430594728.SGD","BK4559","IE00BSNM7G36.USD","LU1291159041.SGD","LU0882574055.USD","LU1983299246.USD","LU1670711040.USD","LU1868836591.USD","LU1032466523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114324713","title":"施贵宝将于2026年ASCO®大会公布新数据，展示其肿瘤学产品组合与下一代管线的创新实力与广度","url":"https://stock-news.laohu8.com/highlight/detail?id=1114324713","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114324713?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:02","pubTimestamp":1779397351,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，将在2026年美国临床肿瘤学会（ASCO®）年会上公布一系列新的研究数据。这些数据将全面展示该公司在肿瘤学领域产品组合及下一代研发管线中科学创新的实力与广度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BSNM7G36.USD","BMY","LU1718418525.SGD","LU1323610961.USD","LU1868837136.USD","BK4532","LU1585245621.USD","LU1883839398.USD","LU1989771016.USD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU1868836914.USD","BK4581","LU0306806265.USD","LU0321505439.SGD","LU2242646821.SGD","IE0009355771.USD","BK4534","LU0114720955.EUR","LU0868494617.USD","IE0002141913.USD","LU1291159041.SGD","LU1430594728.SGD","LU1093756168.USD","LU0061475181.USD","LU0267386448.USD","IE00BFXG1179.USD","BK4007","LU0306807586.USD","LU1868836757.USD","LU0985481810.HKD","LU1670711040.USD","LU1983299246.USD","LU2125154778.USD","LU0096364046.USD","LU1261432733.SGD","LU0225771236.USD","LU0882574055.USD","BK4559","LU1868836591.USD","LU1670710661.SGD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","IE00B2B36J28.USD","LU0237698245.USD","LU1670710588.SGD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0432979614.USD","LU1074936037.SGD","LU2133065610.SGD","LU2242652126.USD","LU1032466523.USD","LU0456855351.SGD","LU2360032135.SGD","LU1670711123.USD","LU0321505868.SGD","BK4588","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636582564","title":"百时美施贵宝向3万名员工全面开放Anthropic公司Claude","url":"https://stock-news.laohu8.com/highlight/detail?id=2636582564","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636582564?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:41","pubTimestamp":1779288087,"startTime":"0","endTime":"0","summary":"　　生物制药巨头百时美施贵宝将为旗下超 3 万名员工接入Anthropic公司的Claude人工智能系统。　　生物制药巨头百时美施贵宝正式引入Anthropic旗舰级 AI 产品Claude，覆盖公司 3 万余名员工，全面深化人工智能与智能助手在药物研发、临床开发及企业日常办公等全场景的应用。　　对百时美施贵宝而言，本次携手Anthropic，是其多年来在集团内部全面落地人工智能战略的延续。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/116/w550h366/20260520/e94d-709299e92d02f68c312a32d4b4c7ff86.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/116/w550h366/20260520/e94d-709299e92d02f68c312a32d4b4c7ff86.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-20/doc-inhyqiyh6272009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4585","BMY","LU1718418525.SGD","LU1323610961.USD","BK4532","LU1585245621.USD","LU1883839398.USD","LU1989771016.USD","LU1093756325.SGD","BK4581","LU0306806265.USD","LU0321505439.SGD","LU2242646821.SGD","BK4534","LU0868494617.USD","LU0114720955.EUR","IE0002141913.USD","LU1291159041.SGD","LU1430594728.SGD","LU1093756168.USD","LU0061475181.USD","LU0267386448.USD","IE00BFXG1179.USD","LU0306807586.USD","LU1868836757.USD","LU0985481810.HKD","LU1670711040.USD","LU1983299246.USD","LU2125154778.USD","LU0096364046.USD","LU1261432733.SGD","LU0225771236.USD","LU0882574055.USD","BK4559","LU1670710661.SGD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","IE00B2B36J28.USD","LU0237698245.USD","LU1670710588.SGD","LU2242652126.USD","IE00BJT1NW94.SGD","LU0432979614.USD","LU1032466523.USD","LU0456855351.SGD","LU1670711123.USD","LU0321505868.SGD","BK4588","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636291840","title":"制药巨头集体拥抱AI智能体：百时美施贵宝(BMY.US)向3万员工推广Claude","url":"https://stock-news.laohu8.com/highlight/detail?id=2636291840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636291840?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:05","pubTimestamp":1779282310,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百时美施贵宝正在向其3万多名员工推广Anthropic的旗舰级Claude AI平台，以此扩大人工智能和AI智能体在研究、临床开发及企业运营中的应用。此外，百时美施贵宝表示，它正在使用Anthropic的编程工具Claude Code来加速其软件和AI的开发。该公司还表示，目前正在评估将Claude AI智能体应用于研究、药物开发以及商业和医学事务等领域。Anthropic的竞争对手OpenAI也已与该行业的关键领头羊达成了合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFXG1179.USD","IE00B2B36J28.USD","LU1868836757.USD","LU0225771236.USD","LU0225284248.USD","LU0432979614.USD","LU0321505439.SGD","LU0237698245.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","LU1670711123.USD","IE00BJT1NW94.SGD","LU0267386448.USD","BK4534","IE0009355771.USD","LU0306807586.USD","LU0868494617.USD","LU1868836591.USD","LU1868836914.USD","IE0002141913.USD","LU1093756325.SGD","LU1983299246.USD","BK4585","LU1670710661.SGD","BK1574","LU2360032135.SGD","LU1032466523.USD","LU1074936037.SGD","LU0061475181.USD","BMY","BK4588","LU2133065610.SGD","BK1191","BK4532","LU0321505868.SGD","LU1323610961.USD","01477","159819","LU1093756168.USD","LU2125154778.USD","LU2242646821.SGD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU2242652126.USD","LU0096364046.USD","LU0114720955.EUR","LU0985481810.HKD","LU2125154935.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147613870","title":"施贵宝与Anthropic达成战略协议，将Claude Enterprise确立为全球运营统一智能平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1147613870","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147613870?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:00","pubTimestamp":1779274829,"startTime":"0","endTime":"0","summary":"施贵宝已宣布与人工智能公司Anthropic达成一项战略协议，计划将Claude Enterprise作为其全球业务运营的统一智能平台。此举旨在通过先进的AI技术整合和优化公司全球范围内的业务流程与数据智能应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0237698245.USD","BK4559","IE0009355771.USD","LU0321505868.SGD","LU0225771236.USD","LU1670711040.USD","LU1983299246.USD","BMY","LU1291159041.SGD","LU1032466523.USD","LU1093756168.USD","LU1670710661.SGD","LU1571399168.USD","LU1261432733.SGD","LU0456855351.SGD","LU1868836914.USD","LU1585245621.USD","IE00BSNM7G36.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0868494617.USD","LU0985481810.HKD","LU0096364046.USD","BK4007","BK4585","LU1989771016.USD","LU1868837136.USD","LU2125154935.USD","BK4532","LU1670711123.USD","IE0002141913.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0306806265.USD","LU0882574055.USD","LU2242652126.USD","LU1883839398.USD","LU2242646821.SGD","BK4534","LU1074936037.SGD","LU0432979614.USD","LU1868836591.USD","LU1093756325.SGD","LU2125154778.USD","LU2133065610.SGD","LU2360032135.SGD","LU0114720955.EUR","LU0306807586.USD","LU1718418525.SGD","IE00BFXG1179.USD","LU0321505439.SGD","BK4588","LU1323610961.USD","LU1430594728.SGD","LU1670710588.SGD","BK4581","LU1868836757.USD","LU0267386448.USD","IE00BJJMRZ35.SGD","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111754724","title":"穆巴达拉投资公司申报持有施贵宝23.34万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1111754724","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111754724?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:21","pubTimestamp":1778854894,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的最新文件，阿布扎比主权财富基金穆巴达拉投资公司披露其持有美国制药巨头施贵宝的股份。申报文件显示，穆巴达拉目前持有施贵宝共计233,437股股票。作为全球领先的主权投资基金之一，穆巴达拉的投资动向常被视为市场风向标。施贵宝作为在肿瘤学、免疫学及心血管疾病领域拥有重磅产品的跨国药企，一直是机构投资者的核心配置标的之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c51812e8550b6fdc2a94c033e7f93915","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1989771016.USD","LU1868836591.USD","LU2125154778.USD","IE0002141913.USD","BK4532","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU0096364046.USD","LU1261432733.SGD","LU1571399168.USD","LU1585245621.USD","LU1718418525.SGD","LU1670711123.USD","LU1670710588.SGD","LU0321505868.SGD","LU1093756168.USD","LU1868836757.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU0456855351.SGD","LU1074936037.SGD","LU1670710661.SGD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU0306807586.USD","IE00BFXG1179.USD","LU1868836914.USD","LU1868837136.USD","LU2133065610.SGD","BK4534","LU1868837300.USD","LU2242646821.SGD","LU0985481810.HKD","LU1323610961.USD","LU0114720955.EUR","LU1670711040.USD","LU0321505439.SGD","LU1291159041.SGD","LU2242652126.USD","LU0061475181.USD","LU0432979614.USD","LU1983299246.USD","LU0267386448.USD","LU1430594728.SGD","LU0237698245.USD","LU1883839398.USD","BMY","LU0306806265.USD","LU2360032135.SGD","BK4559","LU1032466523.USD","LU2125154935.USD","BK4585","BK4581","BK4588","LU0882574055.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102515839","title":"Tempus AI扩大与施贵宝的战略合作，旨在提升肿瘤学和神经科学领域临床开发项目的成功率","url":"https://stock-news.laohu8.com/highlight/detail?id=1102515839","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102515839?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:31","pubTimestamp":1778761900,"startTime":"0","endTime":"0","summary":"Tempus AI正在深化与施贵宝的战略合作关系，此举旨在显著提高双方在肿瘤学及神经科学领域临床开发项目取得成功的可能性。此次合作扩展将进一步整合Tempus AI在人工智能与数据驱动洞察方面的专长，与施贵宝在药物研发领域的深厚经验相结合，共同致力于加速创新疗法的开发进程，并优化临床试验设计。通过强化数据共享与分析能力，双方期望能够更精准地识别潜在的治疗靶点，筛选出更可能受益的患者群体，从而提升整个药物研发管线的效率与成功率，为患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4613","BMY","LU1861559042.SGD","TEMT","BK4611","LU1861558580.USD","BK4121","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780599","title":"百时美施贵宝达成152亿美元中国药物交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780599","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635780599?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:18","pubTimestamp":1778678280,"startTime":"0","endTime":"0","summary":"百时美施贵宝已与江苏恒瑞医药签署了一项合作与许可协议，总金额最高可达152亿美元，使这家美国制药商能够获得一大批早期资产，借此利用中国在早期开发方面的效率。该协议涵盖肿瘤、血液学和免疫学领域的13个早期项目，百时美施贵宝将在2028年前向恒瑞支付高达9.5亿美元，其中包括6亿美元的预付款。该交易预计将于第三季度完成。这笔潜在交易的总规模表明，百时美施贵宝正对中国原研药物进行重大押注。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-13/doc-inhxufva0656828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJT1NW94.SGD","LU2360032135.SGD","LU0096364046.USD","IE0009355771.USD","BK4588","LU0306807586.USD","BK4559","LU1868837136.USD","LU1883839398.USD","LU2133065610.SGD","BK4007","IE00B2B36J28.USD","LU0267386448.USD","BK4585","LU2125154778.USD","IE00BSNM7G36.USD","BMY","IE0002141913.USD","LU0882574055.USD","LU1989771016.USD","LU2125154935.USD","LU1093756325.SGD","IE00BFXG1179.USD","LU0225771236.USD","LU1983299246.USD","IE00BFTCPJ56.SGD","LU1670711040.USD","LU0114720955.EUR","LU1323610961.USD","LU0061475181.USD","LU1093756168.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","BK4532","BK4581","LU0868494617.USD","LU2242646821.SGD","LU1670710588.SGD","LU1868836591.USD","BK4534","LU0985481810.HKD","LU0432979614.USD","LU1261432733.SGD","LU0321505868.SGD","LU1868836914.USD","LU1032466523.USD","LU0237698245.USD","LU0225284248.USD","LU1868837300.USD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635320782","title":"携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635320782","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635320782?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:20","pubTimestamp":1778664054,"startTime":"0","endTime":"0","summary":"5月12日，江苏恒瑞医药股份有限公司(简称“恒瑞医药”，600276.SH;01276.HK)与百时美施贵宝公司(简称“BMS”，NYSE：BMY)宣布达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学领域的早期创新项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735980065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU0225284248.USD","BMY","IE0009355771.USD","LU1571399168.USD","IE00B2B36J28.USD","600276","LU2543165471.USD","01276","LU1670711040.USD","LU2125154778.USD","LU0882574055.USD","BK4532","LU1820825898.SGD","LU2328871848.SGD","BK0060","IE00BFXG1179.USD","BK0183","LU1064131003.USD","LU1261432733.SGD","LU1585245621.USD","LU0432979614.USD","LU1146622755.USD","LU1655091616.SGD","LU2097828557.USD","LU0321505439.SGD","LU1868837300.USD","LU0405327494.USD","LU2097828714.EUR","LU1670710588.SGD","LU0359201612.USD","LU1023057109.AUD","LU1868836591.USD","LU2242652126.USD","LU2242646821.SGD","LU0237698245.USD","LU0225771236.USD","LU1670710661.SGD","LU0405327148.USD","LU0306807586.USD","BK4007","LU0985481810.HKD","LU2495084118.USD","LU1868836757.USD","LU2097828805.USD","IE00BFTCPJ56.SGD","LU1997245177.USD","LU1093756168.USD","LU2097828474.EUR","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161668826","title":"Pacira Biosciences致信股东 重申其董事会提名人选的卓越资质","url":"https://stock-news.laohu8.com/highlight/detail?id=1161668826","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161668826?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:02","pubTimestamp":1778616151,"startTime":"0","endTime":"0","summary":"Pacira Biosciences已向股东致信，再次强调其提名的董事会成员具备卓越的专业资质与经验。\n此举旨在向投资者明确传达，公司推选的董事人选拥有引领公司未来发展的关键能力与深刻行业洞察。信中详细阐述了各位提名人的背景、技能及其能为公司带来的独特价值，以期在即将到来的董事会选举中获得股东的坚定支持。\n公司管理层相信，由这些经验丰富的专业人士组成的董事会，将能有效指导Pacira Biosciences的战略方向，持续为股东创造长期价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","IE00BFXG1179.USD","IE00B2B36J28.USD","LU1868836757.USD","LU0225771236.USD","LU0225284248.USD","BK4007","LU0432979614.USD","BK4581","LU1883839398.USD","LU0321505439.SGD","LU0237698245.USD","LU1868837300.USD","BK4559","LU1571399168.USD","IE00BJJMRZ35.SGD","LU1585245621.USD","LU1670711123.USD","LU1291159041.SGD","LU1868837136.USD","IE00BJT1NW94.SGD","LU0267386448.USD","BK4534","IE0009355771.USD","LU0306807586.USD","LU0456855351.SGD","LU0868494617.USD","LU1868836591.USD","IE0002141913.USD","LU1093756325.SGD","LU1868836914.USD","LU1983299246.USD","BK4585","LU1670710661.SGD","LU1718418525.SGD","LU2360032135.SGD","LU1032466523.USD","LU0882574055.USD","LU1074936037.SGD","LU0061475181.USD","BMY","PCRX","BK4588","LU2133065610.SGD","BK4532","LU0321505868.SGD","LU1989771016.USD","LU1323610961.USD","LU1093756168.USD","LU2125154778.USD","LU2242646821.SGD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU2242652126.USD","LU1670711040.USD","IE00BSNM7G36.USD","LU0096364046.USD","LU0114720955.EUR","LU0985481810.HKD","LU2125154935.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":0.0131},{"period":"3month","weight":-0.033},{"period":"6month","weight":0.0901},{"period":"1year","weight":0.127},{"period":"ytd","weight":0.0591}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.005808},{"month":5,"riseRate":0.553191,"avgChangeRate":0.001393},{"month":6,"riseRate":0.595745,"avgChangeRate":0.009198},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}